Tilray Brands Q4 FY26 earnings call TLRY

Tilray Brands has transformed into a diversified global consumer products and pharmaceutical distribution company, holding leadership positions across cannabis, beverage, hospitality, and wellness. This interconnected model provides consumer reach, brand-building power, operating leverage, and multiple pathways to growth, enabling the company to allocate capital to the highest return opportunities and adapt to evolving markets. The company emphasizes that its long-term growth strategy is not dependent on a single regulatory event or country, providing flexibility that single-category companies lack.

Tilray is uniquely positioned to lead in medical cannabis, leveraging its genetics, cultivation expertise, pharmaceutical manufacturing capabilities, clinical relationships, and international infrastructure. The Portugal facility reached approximately 80% utilization, with a clear path to full capacity, while the German Aphria RX facility is fully utilized. The acquisition of Life in the U.K. further integrates cultivation, manufacturing, clinical care, dispensing, and pharmacy services, providing direct patient access and stronger demand visibility across the patient journey.

The beverage segment grew 6% to $254 million in FY26, including the strategic acquisition of BrewDog in Q4. BrewDog, acquired for approximately $54 million, added over $200 million in annual revenue on a run-rate basis and significantly expanded Tilray's international reach and hospitality footprint. The integration has stabilized operations, improved product availability, and accelerated innovation, demonstrating the power of Tilray's global commercial infrastructure to scale brands into new markets, such as the successful launch of American craft beers in the U.K.

While acknowledging encouraging regulatory momentum, including federal cannabis rescheduling discussions, Tilray's strategy does not rely on a single U.S. regulatory event. The company is prepared to expand its medical cannabis platform in the U.S. when a clear regulatory framework is established, emphasizing the need for FDA approvals and physician-prescribed models similar to Europe. Management remains cautious about M&A in the U.S. until the regulatory path is clear and stable, citing concerns about cost, potential policy changes with new administrations, and the current state silo model.

Tilray's capital allocation decisions are guided by maximizing long-term shareholder value, focusing on opportunities that strengthen operating performance, expand commercial reach, and generate durable cash flow. The company believes its stock price does not fully reflect the value of its global enterprise, balance sheet strength, asset quality, and diversified platform. The focus for fiscal 2027 is on execution, converting assets into stronger margins, higher cash flow, and sustainable profitable growth through organic growth, disciplined acquisitions, innovation, and global expansion.

AI and data-driven technologies are being integrated across all Tilray businesses to enhance productivity, improve margins, and accelerate innovation. This includes optimizing genetics, cultivation yields, demand planning, production, inventory management, and commercial execution in beverage, wellness, pharmaceutical distribution, and hospitality. The company believes AI will strengthen every part of its operations, contributing to improved efficiency and innovation.